checkAd
    Opthea Aktie
    3,3500
     
    USD
    -0,89 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    3,3400
     
    USD
    2.000 STK
    Geldkurs 21.05.24
    3,3900
     
    USD
    100 STK
    Briefkurs 21.05.24
    ISIN: US68386J2087 · WKN: A2QEW7 · SYM: OPT · Australien

    Opthea Bilanz & GuV

    GuV in Mio AUD

    20192020202120222023
    Umsatz0,110,060,070,090,11
    Bruttoergebnis vom Umsatz0,09-0,36-0,50-0,14-0,14
    EBITDA-26,37-16,96-39,16-96,22-138,11
    EBIT0,110,06-39,27-96,30-138,21
    Ergebnis vor Steuer-25,42-16,80-50,28-99,12-148,45
    Ergebnis nach Steuern-14,95-11,08-45,34-92,82-142,52

    Bilanz in Mio AUD

    20192020202120222023
    Aktiva26,4549,44138,4160,0598,64
    Umlaufvermögen25,9149,04138,1259,9198,39
    Summe Anlagevermögen0,540,390,290,140,26
    Passiva26,4549,44138,4160,0598,64
    Summe kurzfristige Verbindlichkeiten4,584,763,1112,0418,74
    Summe langfristige Verbindlichkeiten0,020,110,020,0385,75
    Summe Fremdkapital4,594,873,1212,07104,49
    Bilanzielles Eigenkapital21,8544,57135,2947,98-5,85

    Cashflow in AUD

    20192020202120222023
    Cashflow-17,04 Mio.-5,69 Mio.-45,55 Mio.-71,33 Mio.-120,61 Mio.
    Kennzahlen und Daten von

    Opthea Unternehmensprofil

    Opthea Insidertrades 2024

    Zeitraum 

      Kennzahlen in AUD

      201920202021202220232024e
      Kurs-Gewinn-Verhältnis (KGV)---81,48-6,11-2,20-4,53
      Kurs-Cash-Flow-Verhältnis (KCV)---81,48-7,96-2,59
      Kurs-Buchwert-Verhältnis (KBV)--27,1611,89-
      Kurs-Umsatz-Verhältnis (KUV)--52.9599.1584.225,50
      Umsatz je Aktie0,000,000,000,000,00
      Cashflow je Aktie-0,33-0,11-0,13-1,15-1,63
      Anlageintensität2,00 %1,00 %0,20 %0,20 %0,30 %
      Arbeitsintensität98,00 %99,00 %100,00 %100,00 %100,00 %
      Eigenkapitalquote82,63 %90,15 %97,74 %79,90 %-
      Fremdkapitalquote17,37 %9,85 %2,26 %20,10 %105,93 %
      Verschuldungsgrad21,02 %10,92 %2,31 %25,16 %-
      Working Capital in Mio.30,3864,40135,0147,8779,74
      Deckungsgrad A4.051,07 %11.356,49 %46.386,02 %34.671,33 %-
      Deckungsgrad B4.051,07 %11.356,49 %46.386,02 %34.671,33 %-
      Deckungsgrad C4.049,63 %11.367,70 %---

      Aktieninformationen in AUD

      20192020202120222023
      Aktien im Umlauf in Mio.52,1652,16351,1461,9174,08

      Mitarbeiter

      2024e
      Anzahl Mitarbeiter24


      Aktionärsstruktur

      Profil

      Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The companys development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

      Kennzahlen und Daten von

      Opthea Kontakt

      AdresseAIM Tax-Exempt Funds (Invesco Tax-Exempt Funds)
      Telefon61 3 9826 0399
      Internethttps://opthea.com

      Gold bricht aus, Produzentenaktien mit Kursexplosion